2,2-bis(4-glycidyloxyphenyl)propane has been researched along with Osteoporosis in 2 studies
2,2-bis(4-glycidyloxyphenyl)propane: structure
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Y | 1 |
| Pan, Z | 1 |
| Chen, F | 1 |
| Botolin, S | 1 |
| McCabe, LR | 1 |
2 other studies available for 2,2-bis(4-glycidyloxyphenyl)propane and Osteoporosis
| Article | Year |
|---|---|
Inhibition of PPARĪ³ by bisphenol A diglycidyl ether ameliorates dexamethasone-induced osteoporosis in a mouse model.
Topics: Adipogenesis; Adiposity; Animals; Benzhydryl Compounds; Biomarkers; Bone Marrow; Bone Resorption; Co | 2019 |
Inhibition of PPARgamma prevents type I diabetic bone marrow adiposity but not bone loss.
Topics: Adipocytes; Animals; Benzhydryl Compounds; Biomarkers; Bone Marrow; Cell Differentiation; Cells, Cul | 2006 |